Cervomed announces late-breaking presentations at alzheimer's association® international congress 2025

Boston, july 08, 2025 (globe newswire) -- cervomed inc. (nasdaq: crvo), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver developing topics (late-breaking) virtual and in-person poster presentations at alzheimer's association® international congress (aaic) 2025, being held on july 27 – 31, 2025 in toronto, canada. the company will be presenting the results, including new results, from the rewind-lb phase 2b study of neflamapimod in dementia with lewy bodies (dlb).
CRVO Ratings Summary
CRVO Quant Ranking